Ketoprofen matrix/placebo CHADD Patch — Competitive Intelligence Brief

Ketoprofen matrix/placebo CHADD Patch (Ketoprofen matrix/placebo CHADD Patch) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID (nonsteroidal anti-inflammatory drug). Area: Pain Management / Rheumatology.

phase 3 NSAID (nonsteroidal anti-inflammatory drug) COX-1, COX-2 Pain Management / Rheumatology Small molecule

Target snapshot

Ketoprofen matrix/placebo CHADD Patch (Ketoprofen matrix/placebo CHADD Patch) — ZARS Pharma Inc.. Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ketoprofen matrix/placebo CHADD Patch TARGET	Ketoprofen matrix/placebo CHADD Patch	ZARS Pharma Inc.	phase 3	NSAID (nonsteroidal anti-inflammatory drug)	COX-1, COX-2
Pranoprofen eye drops	Pranoprofen eye drops	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1, COX-2)
optimized ibuprofen	optimized ibuprofen	OSF Healthcare System	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
Ibuprofen/acetaminophen	Ibuprofen/acetaminophen	Montefiore Medical Center	marketed	Analgesic/antipyretic combination (NSAID + non-NSAID analgesic)	Cyclooxygenase (COX-1, COX-2) for ibuprofen; prostaglandin synthesis and central pain pathways for acetaminophen
Non- effervescent Paracetamol kern	Non- effervescent Paracetamol kern	Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina	marketed	Analgesic and antipyretic	Cyclooxygenase (COX-1, COX-2)
Dexketoprofen Trometamol + Paracetamol	Dexketoprofen Trometamol + Paracetamol	Yuzuncu Yil University	marketed	NSAID + analgesic combination	COX-1, COX-2 (dexketoprofen); central prostaglandin synthesis and pain pathways (paracetamol)
Standard Dose Ibuprofen	Standard Dose Ibuprofen	Ottawa Hospital Research Institute	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID (nonsteroidal anti-inflammatory drug) class)

1. Depomed · 1 drug in this class
2. Dong-A ST Co., Ltd. · 1 drug in this class
3. Handok Inc. · 1 drug in this class
4. Imprimis Pharmaceuticals, Inc. · 1 drug in this class
5. Kunming Baker Norton Pharmaceutical Sales Co., Ltd. · 1 drug in this class
6. LEO Pharma · 1 drug in this class
7. Novartis · 1 drug in this class
8. Pfizer · 1 drug in this class
9. University of South Alabama · 1 drug in this class
10. ZARS Pharma Inc. · 1 drug in this class